Compare Stocks → Gold Mania (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EVFMNASDAQ:EVLONASDAQ:NEPTNASDAQ:SPRC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01$0.02$0.01▼$2.63$790K-1.04684,874 shs1.50 million shsEVLOEvelo Biosciences$0.04-18.7%$0.05$0.03▼$13.93$940K1.9419,423 shs22,122 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSPRCSciSparc$1.27+0.8%$2.17$1.15▼$23.66$890K0.71894,412 shs54,386 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences-7.69%-28.36%-42.86%-59.60%-99.51%EVLOEvelo Biosciences-12.12%-12.12%-13.00%+2.59%-98.28%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-59.79%-99.09%SPRCSciSparc+0.79%-3.79%-30.98%-65.77%-92.43%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences2.00HoldN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$18.22M0.04$1.30 per share0.01($2.64) per share0.00EVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00SPRCSciSparc$2.88M0.31N/AN/A$13.57 per share0.09Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%N/AEVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)SPRCSciSparc-$5.12MN/A0.00∞N/AN/AN/AN/A7/1/2024 (Estimated)Latest EVFM, SPRC, NEPT, and EVLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.130.10EVLOEvelo BiosciencesN/A0.480.48NEPTNeptune Wellness SolutionsN/A0.230.10SPRCSciSparcN/A4.103.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%EVLOEvelo Biosciences0.31%NEPTNeptune Wellness Solutions14.44%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%EVLOEvelo Biosciences1.02%NEPTNeptune Wellness Solutions5.10%SPRCSciSparc1.52%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences3761.06 million59.34 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSPRCSciSparc3710,000696,000Not OptionableEVFM, SPRC, NEPT, and EVLO HeadlinesSourceHeadlineSciSparc Ltd. (NASDAQ:SPRC) Sees Large Increase in Short Interestamericanbankingnews.com - April 26 at 3:20 AMSciSparc to acquire AutoMax in strategic mergerinvesting.com - April 13 at 12:33 AMSciSparc Ltd: SciSparc to Acquire AutoMaxfinanznachrichten.de - April 11 at 1:06 PMSciSparc to acquire vehicle importer AutoMaxmsn.com - April 11 at 1:06 PMSciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversificationmsn.com - April 11 at 1:06 PMSciSparc to Acquire AutoMaxglobenewswire.com - April 11 at 8:15 AMSciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depressionglobenewswire.com - March 27 at 8:55 AMSciSparc Ltd: SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Researchfinanznachrichten.de - March 23 at 11:55 AMSciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Researchglobenewswire.com - March 21 at 8:58 AMSciSparc Granted Another Patent, Strengthening its Core Technology in Canadaglobenewswire.com - March 18 at 7:29 AMSciSparc's venture MitoCareX Bio advances AI model for cancer drug discoveryinvesting.com - March 14 at 2:27 PMSciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trialglobenewswire.com - March 14 at 8:49 AMSciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structureglobenewswire.com - March 12 at 8:14 AMAutism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatmentsmsn.com - March 8 at 3:56 PMSciSparc Ltd: SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorderfinanznachrichten.de - March 8 at 10:56 AMSciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorderglobenewswire.com - March 8 at 7:11 AMSciSparc Ltd: SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technologyfinanznachrichten.de - March 7 at 6:36 PMSciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europeglobenewswire.com - March 7 at 7:49 AMSciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technologyglobenewswire.com - March 6 at 4:41 PMSciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosingglobenewswire.com - February 29 at 8:35 AMSciSparc gains as Clearmind partnership yields 3 new international patent applicationsmsn.com - February 27 at 1:26 PMSciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compoundsglobenewswire.com - February 27 at 7:58 AMSciSparc shares up on patents filed for psychedelic compounds with Clearmindmsn.com - February 21 at 8:12 AMSciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compoundsglobenewswire.com - February 20 at 7:14 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEvofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. SciSparcNASDAQ:SPRCSciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.